Rosuvor

Rosuvastatin Ca

Adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-C, Apo B & increasing HDL-C in hyper- & dyslipidemic conditions; primary dysbetalipoproteinemia (type III hyperlipoproteinemia); combined (mixed) dyslipidemia (type IIb); HoFH; slows progression of atherosclerosis in adult patients as part of treatment strategy to lower total-C & LDL-C to target levels. Reduction of total mortality & risk of major CV events in adults w/ increased risk of atherosclerotic CV disease based on presence of CV disease risk markers.

Initially 10 mg once daily, adjust dose after 4-wk interval. Severe hypercholesterolaemia at high CV risk Increase to 40 mg. Patient requiring less agressive LDL-C reduction; Asian patient; w/ predisposing factors to myopathy Initially 5 mg once daily.

May be taken with or without food.

Hypersensitivity. Active liver disease including unexplained, persistent elevations of serum transaminases >3 times ULN; myopathy. Concomitant use w/ cyclosporin. Severe renal impairment (CrCl <30 mL/min). Women of childbearing potential. Pregnancy & lactation.

Discontinue use if ILD develops & creatine kinase >5 times ULN occurs. Not to be used in patients w/ acute, serious condition of myopathy or predisposing to renal failure development secondary to rhabdomyolysis eg, sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders or uncontrolled seizures. Predisposing factors for myopathy/rhabdomyolysis eg, hypothyroidism, history of hereditary muscular disorders, history of muscular toxicity w/ another HMG-CoA reductase inhibitor or fibrate, conditions where increased plasma levels occur. Proteinuria; DM. Assess renal function during routine follow-up. Perform LFT prior to & 3 mth following initiation. Excessive alcohol consumption. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not to be used w/ fusidic acid or w/in 7 days of discontinuation. Not recommended in combination w/ gemfibrozil; PIs. Concomitant use w/ fibrates, niacin. History of hepatic disease. Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Childn <10 yr. Elderly >70 yr.

DM; headache, dizziness; constipation, nausea, abdominal pain; myalgia; asthenia.

Increased plasma conc & risk of myopathy w/ OATP1B1 & BCRP inhibitors. Increased AUC w/ ciclosporin. Increased exposure w/ PIs. Increased C_max & AUC w/ gemfibrozil & other lipid-lowering products. Increased risk of myopathy w/ fenofibrate, other fibrates, niacin (≥1 g daily). Increased AUC w/ ezetimibe. Decreased plasma conc w/ Al- & Mg hydroxide-containing antacids. Decreased AUC & C_max w/ erythromycin. Increased INR w/ vit K antagonist eg, warfarin or other coumarin anticoagulants. Increased ethinylestradiol & norgestrel AUC. Increased risk of myopathy & rhabdomyolysis w/ fusidic acid.

Dyslipidaemic Agents

C10AA07 - rosuvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

B